AHA 2022 In individuals with an increased 10-year ASCVD risk, rosuvastatin 5 mg daily reduced LDL-c, TC, and TG more than fish oil, cinnamon, garlic, turmeric, plant sterols, red yeast rice, or placebo. Moreover, no supplements reduced LDL-c significantly compared with placebo.

In an RCT with 71 participants, low-frequency intermittent fasting for 26 weeks did not alter LDL-c levels compared with an ad libitum diet. However, it did lower insulin resistance and the metabolic syndrome score.

The HAUSER-RCT study showed that in pediatric patients with HeFH, treatment with evolocumab for 24 weeks is safe and reduces LDL-c levels, compared with placebo. But what about the long-term safety and efficacy of evolocumab in this patient population?

In a population-based cohort study, the clinical performance of the 2021 ESC Guidelines for CVD prevention on eligibility of primary prevention with statins was compared with that of the 2019 ESC/EAS, 2016 NICE, and 2013 ACC/AHA guidelines.

ESC 2022 ‘There is a lot of misinformation about how dangerous statins are’ says Prof. Baigent. This analysis showed that there is a small excess of muscle symptoms in the first year after starting statin therapy, but no excess in risk thereafter.

ESC 2022 In the open-label extension of the FOURIER trial, evolocumab maintained LDL-c reduction. Moreover, early treatment initiation was associated with sustained accumulation of CV benefit, including CV death.

ESC 2022 The researchers of this meta-analysis aimed to provide reliable information about the effects of statins on muscle adverse events from double-blind, randomized trials.

A randomized study compared the 3-year efficacy and safety of moderate-intensity statin plus ezetimibe versus high-intensity statin monotherapy in patients with ASCVD.

A network meta-analysis shows both PCSK9i and ezetimibe may reduce non-fatal MI and stroke in adults on maximum statin therapy or with statin intolerance who are at very high or high CVD risk but not in those at moderate or low risk.

The National Lipid Association (NLA) has published a new scientific statement on statin intolerance, which includes a new definition and key consideration for ASCVD risk reduction in patients who are statin intolerant.

In a subanalysis of the ODYSSEY OUTCOMES trial, 95% of patients with recent acute coronary syndrome (ACS) achieved LDL-c <1.4 mmol/L when alirocumab was added to optimal statin therapy, instead of only 17% with placebo.

Watch a discussion by three experts on potential mechanisms, side effects, patient selection, parameters for monitoring and future studies with regard to icosapent ethyl.